Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?

@article{Caon2014DoesSO,
  title={Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?},
  author={J. Caon and M. Paquette and J. Hamm and T. Pickles},
  journal={Prostate Cancer},
  year={2014},
  volume={2014}
}
Background. Prior studies evaluating the effect of statins or acetylsalicylic acid (ASA) on the survival of men receiving prostate cancer were treatment have reported conflicting results, and have not adjusted for comorbidity. Our aim is to investigate the influence of statins and ASA on prostate cancer survival, when comorbidity is adjusted for, in men treated with external beam radiation therapy (EBRT) for prostate cancer. Methods. A cohort of 3851 patients with prostate cancer treated with… Expand
Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study
TLDR
The finding suggests that statins and metformin use after prostate cancer diagnosis may increase survival in patients with hyperlipidemia and radiotherapy. Expand
Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.
TLDR
The study suggests a prognostic impact of statin use in patients receiving abiraterone for mCRPC appears to live longer than those treated with abiraters only, and further studies assessing the use of abiratorone plus statins are warranted. Expand
The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis
TLDR
The association of statins use with biochemical recurrence (BCR) of prostate cancer (PCa) and PCa-specific mortality after definitive therapy and there was a plausible trend towards increasing the BCR-free survival rate among statins users. Expand
The Prognostic Effect of Statin Use on Urologic Cancers
TLDR
While statin use benefited prostate cancer patients in overall survival, cancer-specific survival but not in tumor progression; it also improved biochemical recurrence in radiotherapy patientsbut not in radical patients; and current evidence suggests no benefit ofstatin use to bladder cancer and renal cell carcinoma, except in overall survivors. Expand
Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis
TLDR
In a nationwide cohort study in Denmark, the association between postdiagnosis use of low-dose aspirin and mortality among patients with prostate cancer was examined. Expand
Statin use and mortality of patients with prostate cancer: a meta-analysis
TLDR
Both pre- and postdiagnostic use of statins is associated with better overall survival and PCa-specific survival, which suggests a need for randomized controlled trials of statin use in patients with PCa. Expand
Prognostic value of statin for cancer patients: 
A Meta-analysis.
TLDR
A beneficial effect of statin on all-cause mortality and cancer-specific mortality is presented in patients with cancer, however, further studies are needed to confirm the long term effect. Expand
Nonsteroidal anti-inflammatory drugs and clinical outcomes among men with prostate cancer: A systematic review and meta-analysis
TLDR
Overall, any NSAID use was not associated with PCM, ACM, and BCR among men with PCa, and significant heterogeneity remained in the included studies even after subgroup analyses, that is, no significant association was observed forNSAID use and ACM or BCR overall, and in subgroup by types of NSAIDs use, and NSAIDUse following radiation or surgery. Expand
A Review of Statin Use and Prostate Cancer
TLDR
Future studies should report patients’ anatomic/prognostic stage based on the updated staging system of the American Joint Committee on Cancer, which is a more effective predictor of recurrence and mortality than anatomic stage alone. Expand
Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
TLDR
It is found that statin significantly reduced the all-cause and prostate cancer-specific mortality and improved the BCR in certain subgroup of men with prostate cancer. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 42 REFERENCES
No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer.
OBJECTIVES To examine the effect of concurrent statin use during definitive radiotherapy (RT) on the biochemical outcomes for localized prostate cancer. METHODS A total of 968 patients treated withExpand
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
TLDR
Statin use was associated with a significant improvement in FFBF, FFADT, and RFS in this cohort of men treated with RT for prostate cancer, suggesting the favorable effect of statins may be mediated by direct effect or via the LDL-lowering effect of these medications. Expand
Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
PURPOSE To investigate the association between 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and biochemical and survival outcomes after high-dose radiotherapy (RT) forExpand
[The impact of statins use in clinically localized prostate cancer treated with radical prostatectomy].
TLDR
A relationship, using a univariate analysis, is found between treatment with statins and the presence of insignificant carcinoma in the group with low or intermediate risk of recurrence, however, this relationship is not independent when it is applied to a multivariate analysis. Expand
Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients
TLDR
Overall BCR for the entire cohort was not significantly different between the statin and nonstatin groups, and on multivariate analysis, positive surgical margin and seminal vesicle invasion were independent risk factors for BCR-free survival, whereas other variables were not significant in predicting the risk of BCR. Expand
Statin use is associated with improved prostate cancer survival: is it time for a clinical trial?
  • T. Murtola
  • Medicine
  • Expert review of anticancer therapy
  • 2010
TLDR
It is demonstrated that low low-density lipop protein levels are associated with improved relapse-free survival, supporting the idea that the prostate cancer progression-preventing effects of statins could be, at least in part, mediated by their systemic low- density lipoprotein-lowering effect. Expand
Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer.
  • A. D'Amico
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
An interesting hypothesis regarding statin use and a possible decrease in the risk of PSA recurrence in men undergoing RT that requires prospective validation given the retrospective nature of the study as well as alternative explanations for the findings are raised. Expand
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
TLDR
It is suggested that statins, especially atorvastatin, may improve most clinical presentations with a nonsignificant improvement in 8-year biochemical progression-free survival. Expand
Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.
TLDR
Serum prostate specific antigen is significantly lower in patients with prostate cancer on preoperative statins compared to those not taking these medications, and Prospective studies are required to evaluate if this decrease in prostatespecific antigen leads to later detection of prostate cancer or variations in oncological outcomes. Expand
Statin drugs and risk of advanced prostate cancer.
TLDR
In this cohort of male health professionals, use of statin drugs was not associated with risk of prostate cancer overall but was associated with a reduced risk of advanced (especially metastatic or fatal) prostate cancer. Expand
...
1
2
3
4
5
...